SK Bioscience Co Ltd

SK Bioscience was established in 2018 and has since set its headquarters in Pangyo, Seongnam, Gyeonggi, South Korea. The company has made significant strides in various business segments such as vaccine development, manufacturing, contract development, and manufacturing organization (CDMO) services, alongside life science research and development. An important brand under SK Bioscience's portfolio is the GBP510 COVID-19 vaccine, which is part of its comprehensive vaccine lineup including influenza vaccines. The company has established a strong footprint in the domestic market of South Korea and is expanding its international presence. SK Bioscience’s vaccines and services are sold in several countries globally, with various agreements and approvals for its COVID-19 vaccine supply through collaborations with global organizations and different nations. (Powered by AI)